Apotex Pays Out Over US Price-Fixing Claims
Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
You may also be interested in...
Settlement with the US Department of Justice over criminal price-fixing charges includes donating $50m worth of medicines. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.
Teva has agreed to pay a $225m fine, as well as donating $50m worth of medicines and divesting a product from its portfolio, as part of a settlement with the US Department of Justice over criminal price-fixing charges. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.
As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.